Strength of study evidence examined by the FDA in premarket approval of cardiovascular devices.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of the American Medical Association (JAMA)

• Publication date

  2009-12-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/jama.2009.1899PMID 20040556
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ethical and scientific implications of the globalization of clinical research.

  2009cited by this paper
• Clinical effectiveness of coronary stents in elderly persons: results from 262,700 Medicare patients in the American College of Cardiology-National Cardiovascular Data Registry.

  2009cited by this paper
• The need for improved access to FDA reviews.

  2009cited by this paper
• Does comparative effectiveness have a comparative edge?

  2009cited by this paper
• The Medical Device Safety Act of 2009.

  2009cited by this paper
• Prioritizing comparative-effectiveness research--IOM recommendations.

  2009influential reference
• Ethical and scientific implications of the globalization of clinical research.

  2009cited by this paper
• DTCA for PTCA--crossing the line in consumer health education?

  2008cited by this paper
• Semper fidelis--consumer protection for patients with implanted medical devices.

  2008cited by this paper
• Composite Outcomes in Cardiovascular Research: A Survey of Randomized Trials

  2008cited by this paper
• Direct-to-consumer advertising of medical devices under scrutiny.

  2008cited by this paper
• Assessing Risk of Bias in Included Studies

  2008cited by this paper
• The deregulatory effects of preempting tort litigation: FDA regulation of medical devices.

  2008cited by this paper
• Reporting Bias in Drug Trials Submitted to the Food and Drug Administration: Review of Publication and Presentation

  2008cited by this paper
• Options for slowing the growth of health care costs.

  2008cited by this paper
• The perfect storm of overutilization.

  2008cited by this paper
• Who is Responsible for Evaluating the Safety and Effectiveness of Medical Devices? The Role of Independent Technology Assessment

  2007cited by this paper
• Cardiac Device Implantation in the United States from 1997 through 2004: A Population-based Analysis

  2007cited by this paper
• Addressing rising health care costs--a view from the Congressional Budget Office.

  2007cited by this paper
• Chapter 4 – The Process of Regulatory Review for New Cardiovascular Devices*

  2007cited by this paper
• A novel multi-array immunoassay device for tumor markers based on insert-plug model of piezoelectric immunosensor.

  2007cited by this paper
• Safety issues involving medical devices: implications of recent implantable cardioverter-defibrillator malfunctions.

  2005cited by this paper
• Devices, drugs, and the Food and Drug Administration: increasing implications for ischemic stroke.

  2005cited by this paper
• Maker of heart device kept flaw from doctors.

  2005cited by this paper
• The drug-eluting stent information gap.

  2004cited by this paper
• Medical Device Regulation: An Introduction for the Practicing Physician

  2004influential reference
• Ensuring safe and effective medical devices.

  2003cited by this paper
• Surrogate End Points in Clinical Trials: Are We Being Misled?

  1996cited by this paper

• Nonconcurrent Control Use in FDA Approval of High-Risk Medical Devices

  2025cites this paper
• Scoping review on regulation, implementation and postmarket surveillance of medical devices

  2025cites this paper
• Post Market Data-Real World Safety Evaluation of Pulsed Field Ablation - and Beyond.

  2025cites this paper
• Evaluation of Payer Policies to Reduce Low-Value Medical Device–Based Procedure Use

  2025cites this paper
• Charting a path through high-risk medical device regulation: recommendations from the CORE-MD consortium

  2025cites this paper
• FDA Authorization of Therapeutic Devices Under the Breakthrough Devices Program.

  2025cites this paper
• Late adverse event reporting from medical device manufacturers to the US Food and Drug Administration: cross sectional study

  2025cites this paper
• Worldwide trends in the quality and breadth of clinical investigations of medical devices over the past decade: a scoping review and evidence map

  2025cites this paper
• Clinical Evidence to Support U.S. Food and Drug Administration Review of New Medical Technology in Pulmonary, Sleep and Critical Care Medicine Between 2014 and 2024: A Scoping Review to Support Adoption in Practice.

  2025cites this paper
• The application study of harmonization code in medical device adverse event reporting

  2024cites this paper
• Physicians' Perspectives On FDA Regulation Of Drugs And Medical Devices: A National Survey.

  2024cites this paper
• Reporting of Demographics & Subgroup Analyses in Premarketing Studies of FDA Approved High-Risk Cardiovascular Devices, 2014–2022

  2024cites this paper
• Requirements to bring a medical device to market.

  2024cites this paper
• Class I Recalls of Cardiovascular Devices Between 2013 and 2022

  2024cites this paper
• Characterization of US Food and Drug Administration Class I Recalls from 2018 to 2022 for Moderate- and High-Risk Medical Devices: A Cross-Sectional Study

  2023cites this paper
• Time to publication of cost-effectiveness analyses for medical devices.

  2023cites this paper
• Safety reporting of Essure medical device: a qualitative and quantitative assessment on the FDA manufacturer and user facility device experience database in 2018

  2023cites this paper
• Quality and transparency of evidence for implantable cardiovascular medical devices assessed by the CORE-MD Consortium.

  2023cites this paper
• Studies Of Prescription Digital Therapeutics Often Lack Rigor And Inclusivity.

  2023cites this paper
• Quality and transparency of clinical evidence for high-risk cardiovascular medical devices: a long way to go.

  2023cites this paper
• Different regulatory framework for medical devices and drugs in the European Union: Impact on clinical research and health technology assessments.

  2023cites this paper
• Experts’ Views on FDA Regulatory Standards for Drug and High-Risk Medical Devices: Implications for Patient Care

  2022cites this paper
• A Policy Approach to Reducing Low-Value Device-Based Procedure Use.

  2022cites this paper
• The FDA and Ensuring Safety and Effectiveness of Devices, Biologics, and Technology.

  2022cites this paper
• US Food and Drug Administration-Mandated Postmarketing Studies for High-risk Cardiovascular Devices Approved 2015-2019.

  2022cites this paper
• Risk of Recall Among Medical Devices Undergoing US Food and Drug Administration 510(k) Clearance and Premarket Approval, 2008-2017

  2021cites this paper
• Fatalities possibly associated with hyaluronic acid injections: a review of events reported to the FDA

  2021cites this paper
• Untact Management of Patients with Chronic Kidney Diseases

  2021cites this paper
• FDA Regulation and Approval of Medical Devices: 1976-2020.

  2021cites this paper
• Reporting of Death in US Food and Drug Administration Medical Device Adverse Event Reports in Categories Other Than Death.

  2021cites this paper
• Generating comparative evidence on new drugs and devices after approval.

  2020cites this paper
• Generating comparative evidence on new drugs and devices before approval.

  2020cites this paper
• Comparison of Priority vs Standard US Food and Drug Administration Premarket Approval Review for High-Risk Medical Devices.

  2020cites this paper
• Patient Perceptions on a Non-Blinded Randomized Trial of Radiotherapy Technologies: A Novel Survey Study Exploring Therapeutic Misconception.

  2020cites this paper
• Early experience with the FDA’s Breakthrough Devices program

  2020cites this paper
• Endoscopic transmission of carbapenem-resistant Enterobacteriaceae: implications for Food and Drug Administration approval and postmarket surveillance of endoscopic devices.

  2020cites this paper
• Global Regulatory Review Needed for Cochlear Implants: A Call for FDA Leadership

  2020cites this paper
• Effect of number of crowns on the crush resistance in open-cell stent design

  2020cites this paper
• Device Safety.

  2019cites this paper
• Cybersecurity features of digital medical devices: an analysis of FDA product summaries

  2019cites this paper
• Evaluation of technologies approved for supplemental payments in the United States

  2019cites this paper
• Premarket evaluation of medical devices: a cross-sectional analysis of clinical studies submitted to a German ethics committee

  2019cites this paper
• FDA Premarket Approval Supplements and Medical Device Safety and Effectiveness

  2019cites this paper
• The Controversy Over Essure Birth Control

  2019cites this paper
• Miscategorization of Deaths in the US Food and Drug Administration Adverse Events Database.

  2019cites this paper
• Defining the clinician’s role in early health technology assessment during medical device innovation – a systematic review

  2019cites this paper
• Quality of reporting in randomized controlled trials of therapeutic cardiovascular medical devices☆

  2019cites this paper
• QUALITY ASSURANCE OF REGISTRIES FOR HEALTH TECHNOLOGY ASSESSMENT

  2018cites this paper
• Harmonizing Standards and Incentives in Medical Device Regulation: Lessons Learned from the Parallel Review Pathway

  2018cites this paper
• An assessment of contemporary bone conduction devices

  2018cites this paper
• FDA recommends “modernizing” review of devices in wake of global investigation

  2018cites this paper
• The need for transparency of clinical evidence for medical devices in Europe.

  2018cites this paper
• The Comparing Options for Management: PAtient‐centered REsults for Uterine Fibroids (COMPARE‐UF) registry: rationale and design

  2018cites this paper
• Assessment of Clinical Trial Evidence for High-Risk Cardiovascular Devices Approved Under the Food and Drug Administration Priority Review Program

  2018cites this paper
• Reducing FDA regulations for medical devices: cutting red tape or putting patients’ lives at risk?

  2018cites this paper
• Public Participation in Drafting of the 21st Century Cures Act

  2017cites this paper
• Combined Drugs and Procedure Trials

  2017cites this paper
• Food and Drug Administration's Humanitarian Device Exemption Marketing Approval Pathway: Insights for Developing Devices for Rare Diseases

  2017cites this paper
• Ultrasonic vs. radiofrequency energy sealing of the cystic duct in chronic cholecystitis patients

  2017cites this paper
• Major FDA medical device recalls in ophthalmology from 2003 to 2015.

  2017cites this paper
• Drug Delivery Systems: A Regulatory Perspective

  2017cites this paper
• Hips, Knees, and Hernia Mesh: When Does Gender Matter in Surgery?

  2017cites this paper
• Incremental Revisions across the Life Span of Ophthalmic Devices after Initial Food and Drug Administration Premarket Approval, 1979-2015.

  2017cites this paper
• The Methodology of Clinical Studies Used by the FDA for Approval of High-Risk Orthopaedic Devices

  2017cites this paper
• Teaching Hospitals and the Disconnect Between Technology Adoption and Comparative Effectiveness Research: The Case of the Surgical Robot

  2017cites this paper
• Multiple constraints compromise decision-making about implantable medical devices for individual patients: qualitative interviews with physicians

  2017cites this paper
• Device Safety Implications of the Clinical Data Leading to US Food and Drug Administration Approval of Soft-Tissue Fillers

  2017cites this paper
• Hysteroscopic Sterilization With Essure: Summary of the U.S. Food and Drug Administration Actions and Policy Implications for Postmarketing Surveillance.

  2017cites this paper
• Characteristics of Clinical Studies Used for US Food and Drug Administration Approval of High-Risk Medical Device Supplements

  2017cites this paper
• Clinical Evidence Supporting US Food and Drug Administration Premarket Approval of High-Risk Otolaryngologic Devices, 2000-2014

  2017cites this paper
• FDA Device Regulation.

  2017cites this paper
• An in Vitro Twist Fatigue Test of Fabric Stent-Grafts Supported by Z-Stents vs. Ringed Stents

  2016cites this paper
• How do Orthopaedic Devices Change After Their Initial FDA Premarket Approval?

  2016cites this paper
• Comparing drug and non-drug technologies in comparative effectiveness research

  2016cites this paper
• Evaluating Sex Differences in Medical Device Clinical Trials

  2016cites this paper
• Registries for health technology assessment: Back to the future.

  2016cites this paper
• Comparison of rates of safety issues and reporting of trial outcomes for medical devices approved in the European Union and United States: cohort study

  2016cites this paper
• Clinical trials of image‐guided interventions including radiotherapy studies

  2016cites this paper
• Medical Device Approvals Through the Premarket Approval Pathway in Obstetrics and Gynecology From 2000 to 2015: Process and Problems.

  2016cites this paper
• Overview of High-Risk Medical Device Innovation in Gastroenterology from 2000 to 2014: Enhancing the Pipeline

  2016cites this paper
• Approbation, mise en marché et surveillance après mise en marché des dispositifs médicaux à risque élevé : examen des enjeux socio-éthiques

  2015influential citation
• Recent Trends in Orthopedic Device Regulation.

  2015cites this paper
• Selective reporting in trials of high risk cardiovascular devices: cross sectional comparison between premarket approval summaries and published reports

  2015cites this paper
• Evaluating the Feasibility of Cost-effectiveness Analyses of Medical Devices through Clinical Trial Data

  2015cites this paper
• Medical Device Postapproval Safety Monitoring: Where Does the United States Stand?

  2015cites this paper
• The 21st Century Cures Act--Will It Take Us Back in Time?

  2015cites this paper
• Postmarket Modifications of High-Risk Therapeutic Devices in Otolaryngology Cleared by the US Food and Drug Administration

  2015cites this paper
• Characteristics of Clinical Studies Conducted Over the Total Product Life Cycle of High-Risk Therapeutic Medical Devices Receiving FDA Premarket Approval in 2010 and 2011.

  2015cites this paper
• Implications of the Institute of Medicine Report: Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease

  2015cites this paper
• Too much technology

  2015cites this paper
• FDA Policy and Cardiovascular Medicine.

  2015cites this paper
• Preventing adhesion on medical devices

  2015cites this paper
• Does assessing the value for money of therapeutic medical devices require a flexible approach?

  2015cites this paper
• The 21st century cures act: Opportunities and challenges

  2015cites this paper
• Post-market clinical research conducted by medical device manufacturers: a cross-sectional survey

  2015cites this paper
• Pivotal clinical trials of novel ophthalmic drugs and medical devices: retrospective observational study, 2002–2012

  2015cites this paper
• Essays in the Economics of Health Care and the Regulation of Medical Technology

  2014cites this paper
• A proposed framework to improve the safety of medical devices in a Canadian hospital context

  2014cites this paper
• Stent fabric fatigue of grafts supported by Z-stents versus ringed stents: An in vitro buckling test

  2014cites this paper
• Improving medical device regulation: the United States and Europe in perspective.

  2014cites this paper